These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37537670)

  • 21. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
    Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
    Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rare essentials: drugs for rare diseases as essential medicines.
    Stolk P; Willemen MJ; Leufkens HG
    Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of the rare disease and Orphan Drug Act in Taiwan.
    Hsiang NC; Huang WF; Gau CS; Tsai TW; Chang LC
    J Food Drug Anal; 2021 Dec; 29(4):717-725. PubMed ID: 35649145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 31. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Orphan drugs and drug pirates].
    Bannenberg WJ; 't Hoen EFM
    Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases.
    Brown DG; Wobst HJ
    Bioorg Med Chem; 2023 Feb; 80():117170. PubMed ID: 36696875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
    Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
    Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One drug to treat many diseases: unlocking the economic trap of rare diseases.
    Pierzynowska K; Kamińska T; Węgrzyn G
    Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development.
    Heslop E; Csimma C; Straub V; McCall J; Nagaraju K; Wagner KR; Caizergues D; Korinthenberg R; Flanigan KM; Kaufmann P; McNeil E; Mendell J; Hesterlee S; Wells DJ; Bushby K;
    Orphanet J Rare Dis; 2015 Apr; 10():49. PubMed ID: 25902795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.